The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 365-369

  Camps, Carlos ^a   Jantus Lewintre, Eloisa ^a   Cabrera, Andrea ^a   Blasco, Ana ^a   Sanmartín, Elena ^a   Gallach, Sandra ^a   Caballero, Cristina ^a   Del Pozo, Nieves ^a   Rosell, Rafael ^b   Guijarro, Ricardo ^a   Sirera, Rafael ^a,c  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

KRAS; Molecular markers; Non small cell lung cancer (NSCLC); Prognostic factors

Indexed keywords

CISPLATIN; DNA; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CODON; DISEASE COURSE; DNA EXTRACTION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PLASMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL ANALYSIS;

EID: 79955483992     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.09.005     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Schatzkin A., Freedman L.S., Schiffman M.H., Dawsey S.M. Validation of intermediate end points in cancer research. J Natl Cancer Inst 1990, 82:1746-1752.
3. Birrer M.J., Brown P.H. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res 1992, 52:2658s-2664s.
4. Mao L., Hruban R.H., Boyle J.O., Tockman M., Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994, 54:1634-1637.
5. Mills N.E., Fishman C.L., Scholes J., Anderson S.E., Rom W.N., Jacobson D.R. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 1995, 87:1056-1060.
6. Keohavong P., DeMichele M.A., Melacrinos A.C., Landreneau R.J., Weyant R.J., Siegfried J.M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996, 2:411-418.
7. Harris C.C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991, 51:5023s-5044s.
8. Stanley L.A. Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes. Toxicology 1995, 96:173-194.
9. Campbell S.L., Khosravi-Far R., Rossman K.L., Clark G.J., Der C.J. Increasing complexity of Ras signaling. Oncogene 1998, 17:1395-1413.
10. Rodenhuis S., Slebos R.J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992, 52:2665s-2669s.
11. Huncharek M., Muscat J., Geschwind J.F. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999, 20:1507-1510.
12. Graziano S.L., Gamble G.P., Newman N.B., Abbott L.Z., Rooney M., Mookherjee S., et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999, 17:668-675.
13. Mulcahy H.E., Lyautey J., Lederrey C., qi C.X., Anker P., Alstead E.M., et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998, 4:271-275.
14. Cho J.Y., Kim J.H., Lee Y.H., Chung K.Y., Kim S.K., Gong S.J., et al. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer 1997, 79:462-467.
15. Fukuyama Y., Mitsudomi T., Sugio K., Ishida T., Akazawa K., Sugimachi K. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 1997, 75:1125-1130.
16. Bremnes R.M., Sirera R., Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer 2005, 49:1-12.
17. Kopreski M.S., Benko F.A., Borys D.J., Khan A., McGarrity T.J., Gocke C.D. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000, 92:918-923.
18. Ryan B.M., McManus R.O., Daly J.S., Keeling P.W., Weir D.G., Lefort F., et al. Serum mutant K-ras in the colorectal adenoma-to-carcinoma sequence, Implications for diagnosis, postoperative follow-up, and early detection of recurrent disease. Ann N Y Acad Sci 2000, 906:29-30.
19. Ramirez J.L., Sarries C., de Castro P.L., Roig B., Queralt C., Escuin D., et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003, 193:207-216.
20. Sorenson G.D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000, 6:2129-2137.
21. Anker P., Lefort F., Vasioukhin V., Lyautey J., Lederrey C., Chen X.Q., et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997, 112:1114-1120.
22. Kimura T., Holland W.S., Kawaguchi T., Williamson S.K., Chansky K., Crowley J.J., et al. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci 2004, 1022:55-60.
23. Camps C., Sirera R., Bremnes R., Blasco A., Sancho E., Bayo P., et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?. Lung Cancer 2005, 50:339-346.
24. Wang S., An T., Wang J., Zhao J., Wang Z., Zhuo M., et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:1324-1330.
25. Bearzatto A., Conte D., Frattini M., Zaffaroni N., Andriani F., Balestra D., et al. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002, 8:3782-3787.
26. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
27. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
28. Yakubovskaya M.S., Spiegelman V., Luo F.C., Malaev S., Salnev A., Zborovskaya I., et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995, 63:810-814.
29. Dziadziuszko R., Jassem E., Jassem J. Clinical implications of molecular abnormalities in lung cancer. Cancer Treat Rev 1998, 24:317-330.
30. Custodio A.B., Gonzalez-Larriba J.L., Bobokova J., Calles A., Alvarez R., Cuadrado E., et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol 2009, 4:891-910.
31. Sorenson G.D., Pribish D.M., Valone F.H., Memoli V.A., Bzik D.J., Yao S.L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994, 3:67-71.
32. Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994, 86:774-779.
33. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11:5878-5885.
34. Hunt J.D., Strimas A., Martin J.E., Eyer M., Haddican M., Luckett B.G., et al. Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiol Biomarkers Prev 2002, 11:1405-1412.
35. Gautschi O., Huegli B., Ziegler A., Gugger M., Heighway J., Ratschiller D., et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 2007, 254:265-273.
36. Mitsudomi T., Viallet J., Mulshine J.L., Linnoila R.I., Minna J.D., Gazdar A.F. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991, 6:1353-1362.
37. Gao H.G., Chen J.K., Stewart J., Song B., Rayappa C., Whong W.Z., et al. Distribution of p53 and K-ras mutations in human lung cancer tissues. Carcinogenesis 1997, 18:473-478.
38. Slebos R.J., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J., Meijer C.J., et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990, 323:561-565.
39. Iyengar P., Tsao M.S. Clinical relevance of molecular markers in lung cancer. Surg Oncol 2002, 11:167-179.
40. Tsao D.A., Yang M.J., Chang H.J., Yen L.C., Chiu H.H., Hsueh E.J., et al. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients. Lung Cancer 2010, 68:51-57.